In this Issue:
Telbivudine: renal protective effect
Ribavirin may promote PEG-IFNα-2a responsiveness
. . . or may not
Predicting an SVR to PEG-IFN/ribavirin in GT1 chronic HCV infection
. . . . without requiring additional PI treatment
Predicting progression to chronic infection after AHB
Peritransplant ALC: predicts HCV recurrence, patient survival
Using PIs to treat HCV after liver transplantation
Renal impairment with boceprevir or telaprevir
Hepatic events in HCV with inherited bleeding disorders
Please login below to download this issue (PDF)